Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

43 results about "Challenge tests" patented technology

Sterilization indicator test packs

Sterilization indicator test packs for testing the effectiveness of a sterilization procedure are provided. Both non-challenge and challenge-type test packs are disclosed. The non-challenge test packs include generally comprise a tray for holding a sterilization indicator the tray containing an elevated rim surface defining the perimeter of the tray and a recessed trough for receiving a sterilization indicator. The rim surface includes a plurality of spaced-apart grooves along its length extending through the rim to the recessed trough; a sterilization indicator within the recessed trough of the tray; and a lid that forms a plurality of channels with the grooves in the tray such that sterilant can enter the tray through the channels and contact the sterilization indicator.
The challenge-type test packs generally include a tray for holding a sterilization indicator, the tray comprising a substantially planar surface, a recessed trough for receiving a sterilization indicator, and a recessed groove of a defined length and cross-sectional area extending through the recessed trough and penetrating the edge of the tray; a sterilization indicator within the recessed trough of the tray; and a lid forming a substantially sterilant-impermeable seal with the planar surface of the tray and forming a lumen path with the recessed groove in the tray.
Owner:3M INNOVATIVE PROPERTIES CO

Riemerella anatipestifer blood serum 1 type genetic engineering attenuated strain and construction method thereof

The invention discloses an attenuated bacterial strain of Riemerella anatipestifer serum type 1 genetic engineering and a method for constructing the same, the method comprises the steps of: performing Sal I single enzyme digestion to a suicide plasmid pDS-132 and a Riemerella anatipestifer serotype 1 gene delta AcOAT, respectively, and using T4DNA ligase for connection to obtain pDS132::delta AcOAT suicide plasmid; transferring pDS-132:: delta AcOAT into a Riemerella anatipestifer serotype 1 gene GDGZ strain competent cell by electrotransformation, and screening recombinant mutant strains with a chloramphenicol resistant plate to obtain the attenuated strain of Riemerella anatipestifer serum type 1 genetic engineering. Animal tests show that 10-time LD50 dosage challenge tests show that the virulence of the attenuated strain has decreased remarkably without virulence basically and the attenuated strain can not reverse to virulence from avirulence and has the potential for preparing attenuated live vaccine.
Owner:INST OF ANIMAL HEALTH GUANGDONG ACADEMY OF AGRI SCI

Classical swine fever E2 subunit vaccine and application thereof

InactiveCN106139139AThe effective amount of antigen is stableLess side effectsViral antigen ingredientsVirus peptidesImmune effectsAdjuvant
The invention provides a classical swine fever E2 subunit vaccine and a preparation method thereof. The preparation method specifically comprises the steps that a Baculovirus Carrier Expression System is used for expressing a large amount of recombination classical swing fever E2 protein in insect cells, and the classical swine fever E2 subunit vaccine with a good immune effect is developed. The Bac-to-Bac Baculovirus Carrier Expression System is used for expressing the classical swine fever E2 protein. The classical swine fever E2 protein and an adjuvant 201R are emulsified into the novel subunit vaccine, and by means of piglet immune challenge tests, it is verified that the subunit vaccine has a good immune protection effect.
Owner:北京大北农科技集团股份有限公司动物医学研究中心 +3

Indometacin and albuterol suppository, preparation method, detection method and application thereof

The invention provides an indometacin and albuterol suppository and a preparation method of the suppository; the suppository comprises effective dose of indometacin, effective dose of albuterol, a dispersing agent, emulsifier and a molding agent. The preparation method comprises the steps of dissolving the indometacin and the albuterol in the dispersing agent, then mixing with the molten molding agent and the emulsifier, and homogenizing to obtain the suppository. The suppository provided by the invention is featured with smooth production and uniform quality; and auxiliary materials do not influence content detection; wherein content detection recovery rate of the albuterol reaches 97%, and content uniformity A+1.8S is less than 10, and is superior to a requirement that content uniformity A+1.8S of a suppository is less than 25 (Department 2 of Chinese Pharmacopoeia 2005 edition, Page 75 of Appendix XE); and layering and precipitation do not appear after the suppository is subjected to a challenge test at 45 degrees centigrade for 72 hr.
Owner:LIVZON GROUP LIVZON PHARMA FACTORY +1

Preparation method and application of Brucella multi-epitope fusion protein vaccine

The invention discloses a Brucella multi-epitope fusion protein antigen. Amino acid sequences of dominant epitopes of Brucella outer membrane proteins BP26, OMP31, OMP16 and OMP2b are in series connection to construct a fusion protein gene to express the proteins, and a Brucella multi-epitope fusion protein antigen vaccine is prepared. Mice challenge tests show that the Brucella multi-epitope fusion protein antigen vaccine plays a role in immune protection in Brucella infection.
Owner:JILIN UNIV

Calcium challenge test for detecting calcium homeostasis disorders

The invention provides simple methods for detecting disorders of a subject's calcium homeostasis. The methods include administering a calcium salt to the subject and observing the effect of this dose of calcium on calcium levels in the subject's bodily fluids and / or tissues. The methods are useful to detect certain calcium homeostasis disorders or a predisposition for such disorders including adynamic bone disease and soft tissue calcification disorders, which are difficult to detect by other methods.
Owner:SCANTIBODIES LAB

Method for detection effectiveness of aftosa inactivated vaccines

The invention relates to a method for detecting the effectiveness of aftosa inactivated vaccines. The method comprises the following steps that firstly, each dose of each batch of vaccines immunizes 4 to 8 Balb / C series rats, the immunizing dose of the vaccines can be classified into 1 rat / part, one-second rat / part and one-fourth rat / part, blood sampling is performed on the twenty-eighth day, and serum is separated; secondly, serum specific antibodies are detected through an aftosa inhibiting ELISA method, and if antibody inhibiting ELISA titer-log10X is higher than 2.0 and variable coefficient is lower than 12 percent, the antibodies are judged to be qualified. The invention provides a novel method for detecting the effectiveness of aftosa inactivated vaccine, immunizing Balb / C series rats and detecting serum through the method can properly reflect the effective antigen content in the vaccines, and the method replaces the original animal immunization challenge test.
Owner:CHINA INST OF VETERINARY DRUG CONTROL

Method for producing aviadenovirus 4 type vaccine by using LMH cell line, and vaccine

The invention belongs to the technical field of veterinary biological products, and particularly relates to a method for producing an aviadenovirus 4 type vaccine by using an LMH cell line, and the vaccine. The LMH cell cultured by utilizing the method provided by the invention is used for culturing an aviadenovirus 4 type, so that the production cost can be greatly reduced, and meanwhile, the titer of the virus is ensured; through the process, within the shortest time 60h, the aviadenovirus 4 type virus with the titer being more than 108.5TCID50 / 0.1ml can be stably obtained, so that comparedwith the prior art, the remarkable technological advantage is realized. According to the vaccine prepared from a vaccine antigen with high titer, the immunity of the vaccine can be remarkably improved, and the immune challenge test result proves that 100 percent of protection can be realized on the attack of the aviadenovirus 4 type.
Owner:广州渔跃生物技术有限公司 +1

Preparation method for inactivated vaccine against avian pasteurellosis

InactiveCN105288607AGood immune protectionAntibacterial agentsBacteriaPasteurella aviumPasteurella multocida type
The invention discloses a preparation method for an inactivated vaccine against avian pasteurellosis. The preparation method comprises the following steps: preparation of a strain used for production; preparation of bacterial liquid used for vaccine preparation; inactivation of the bacterial liquid used for vaccine preparation; and preparation of the vaccine. According to the method, avian Pasteurella multocida type A is used as the original strain; the strain undergoes culture in an iron-limited environment so as to obtain the bacterial liquid eventually; and the bacterial liquid is mixed with a white oil adjuvant so as to prepare the inactivated vaccine against avian pasteurellosis. A local chicken is immunized with the vaccine prepared by using the method, then challenge test is carried out, and results show than a protection rate reaches 100%, so it is proved that the vaccine exerts good immunoprotection effect.
Owner:INST OF ANIMAL SCI & VETERINARY HUBEI ACADEMY OF AGRI SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products